Zhao B, et al. - Researchers evaluated the incidence and risk of developing serious adverse events (SAEs) or fatal adverse events (FAEs) in cancer patients after nivolumab treatment. From inception to June 2018, PubMed and Embase were used to identify phase 2 and phase 3 nivolumab trials; data on SAEs/FAEs from each study was then extracted and pooled to calculate the overall incidence and odds ratios. They analyzed a total of 21 trials with 6,173 cancer patients. No increased risk of SAEs or FAEs was noted with nivolumab treatment vs conventional treatment. The most common toxicities were seen in the respiratory (21.4%), gastrointestinal (7.7%), and hepatic systems (6.6%). Most SAEs/FAEs were attributed to pneumonitis. Overall, nivolumab is a relatively safe antitumor agent, but nononcologists should still be advised of the possible adverse events.